Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

β2-Microglobulin antibody inhibition of androgen receptor expression and survival in prostate cancer

Wen-Chin Huang, Haiyen E. Zhau, WeiPing Qian, Hui-Wen Lue, Chia-Yi Chu and Leland W. K. Chung
Wen-Chin Huang
Emory University Winship Cancer Institute, Atlanta, GA, Georgia State University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haiyen E. Zhau
Emory University Winship Cancer Institute, Atlanta, GA, Georgia State University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WeiPing Qian
Emory University Winship Cancer Institute, Atlanta, GA, Georgia State University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui-Wen Lue
Emory University Winship Cancer Institute, Atlanta, GA, Georgia State University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia-Yi Chu
Emory University Winship Cancer Institute, Atlanta, GA, Georgia State University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leland W. K. Chung
Emory University Winship Cancer Institute, Atlanta, GA, Georgia State University, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2008
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

Abstract

2553

We previously reported that β2-microglobulin (β2M) promoted osteomimicry and cell proliferation through a cAMP-dependent protein kinase A (PKA) signaling pathway in human prostate cancer cells. Targeting β2M and its signaling axis using β2M siRNA induced apoptotic death of prostate cancer cells in vitro and in vivo as subcutaneous and bone tumor xenografts (Huang, et al. Cancer Res. 65:2303-13, 2005; and 66:9108-16, 2006). In this presentation, we utilized anti-β2M antibody (β2M Ab) as a new approach to block the β2M signaling and observed the effect on expression of the androgen receptor (AR) and its target gene, prostate-specific antigen (PSA), and cell growth and survival in prostate cancer cells. Treatment of AR- and PSA-positive prostate cancer cell lines, LNCaP (androgen-dependent) and its lineage-related C4-2B (androgen-independent) cells with β2M Ab resulted in a dose-dependent inhibition of AR and PSA mRNA and protein expression determined by RT-PCR and Western blot; this inhibitory effect was attenuated by purified β2M protein. We further demonstrated that the decrease of AR and PSA expression mediated by β2M Ab was through down-regulation of phosphorylated extracellular signal-regulated kinase (ERK, p44/p42) and a nuclear transcription factor, sterol regulatory element binding protein-1 (SREBP-1). β2M Ab also showed to induce prostate cancer cell programmed death as indicated by activation of apoptotic markers, cleaved caspase-9, caspase-3 and PARP, and inhibition of survivin expression. β2M Ab, however, exhibited low toxicity in normal human prostate epithelial and stromal cells. β2M Ab, when administered to mice bearing prostate tumors, was shown to decrease greatly AR and induce marked prostate tumor death as demonstrated by immunohistochemical analysis and M30 CytoDeath marker staining compared to the control groups. These exciting findings suggested that interrupting β2M and its signaling axis by using a novel β2M Ab may provide a promising and safe therapeutic approach for the treatment of human prostate cancer and its progression.

Footnotes

  • 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 68 (9 Supplement)
May 2008
Volume 68, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
β2-Microglobulin antibody inhibition of androgen receptor expression and survival in prostate cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
β2-Microglobulin antibody inhibition of androgen receptor expression and survival in prostate cancer
Wen-Chin Huang, Haiyen E. Zhau, WeiPing Qian, Hui-Wen Lue, Chia-Yi Chu and Leland W. K. Chung
Cancer Res May 1 2008 (68) (9 Supplement) 2553;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
β2-Microglobulin antibody inhibition of androgen receptor expression and survival in prostate cancer
Wen-Chin Huang, Haiyen E. Zhau, WeiPing Qian, Hui-Wen Lue, Chia-Yi Chu and Leland W. K. Chung
Cancer Res May 1 2008 (68) (9 Supplement) 2553;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

New Approaches to Biological Therapy: Oral Presentations - Proffered Abstracts

  • Co-treatment with vorinostat and Aurora kinase inhibitor MK-0457 exerts synergistic antileukemia activity against AML and CML cells, including those expressing mutant Bcr-AblT315I
  • Immunotoxin and paclitaxel synergy results from a decrease in shed target antigen levels in the extracellular space of tumors
  • Combination of a monoclonal anti-phosphatidylserine antibody with docetaxel strongly inhibits the growth and metastasis of hormone-refractory prostate cancers in mice
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement